Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar ...

Quick Read Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two ...

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...